ANN ARBOR, Mich., June 25 /PRNewswire/ -- Accuri Cytometers, Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the appointment of Daniel J. Calvo and George W. Dunbar to newly created positions on its Board of Directors.
“We are fortunate to have recruited these two outstanding individuals to our Board who are located in our own community,” said Jennifer Baird, Chief Executive Officer of Accuri. “George and Dan have a wealth of successful strategic and operational experience in growing life sciences organizations and taking them to the next level, with expertise spanning early stage to global scale organizations. The fact that our region increasingly is home to senior executives of this caliber is a testament to the vitality of the Ann Arbor life sciences sector. Dan’s and George’s proximity to Accuri should enable us to benefit from their expertise on an ongoing basis as we continue our preparations for the commercial launch of our Accuri C6 Flow Cytometer(TM).”
George Dunbar is currently President, CEO and a Director of Aastrom Biosciences, a publicly traded company specializing in autologous stem cell products for use in regenerative medicine. He has more than 30 years experience in the biotech, pharmaceutical, diagnostic and device sectors and has served as CEO for more than half of his career in both established and early-stage life sciences companies. Prior to Aastrom, Mr. Dunbar served as Chief Executive Officer for a variety of successful public and private life science companies including Quantum Dot Corporation, an innovative research tools company acquired by Invitrogen; Targesome; Epic Therapeutics; Cytotherapeutics; Stem Cells and Metra Biosystems. Earlier in his career, Mr. Dunbar held management positions with the Ares-Serono Group and Amersham International.
“Accuri’s innovative bench-top flow cytometer system is that rare phenomenon--a genuinely disruptive technology,” said Mr. Dunbar. “For the first time, it gives scientists everywhere the ability to access flow cytometry on a routine basis, which should drive its large scale commercial adoption. I am delighted to have the opportunity to serve on the Accuri Board.”
Dan Calvo has more than 25 years experience in managing life and health sciences businesses, and is currently President and CEO of Assay Designs, which provides innovative and easy-to-use research assays and reagents to the worldwide biomedical, pharmaceutical and translational research communities. Prior to Assay Designs, Mr. Calvo was CEO of Cellomics, an innovator in high content screening that was acquired by Fisher Scientific. Previously, he held senior operating positions at major established providers of life sciences research products. Mr. Calvo headed the worldwide sales and service function at PerkinElmer Life and Analytical Sciences, where he more than doubled sales to half a billion dollars. At NEN Life Sciences, Mr. Calvo helped drive a significant turnaround prior to the company’s acquisition by PerkinElmer. Earlier in his career, Mr. Calvo held positions of increasing responsibility in DuPont’s Medical Products business.
“My enthusiasm for the Accuri C6 Flow Cytometer reflects my quarter century of experience overseeing the successful development and commercialization of novel life science research products,” said Mr. Calvo. “Accuri’s strategy of mobilizing an interdisciplinary team to completely redesign its flow cytometer from the ground up offers the potential to achieve the capabilities of the most advanced flow cytometers with much greater ease of use and at a fraction of the cost. This breakthrough will put the capabilities of flow cytometry on the bench-top, and expand cellular science in research, drug discovery, and clinical settings. I look forward to working with the Accuri team as they advance the C6 Flow Cytometer System toward the market.”
Explicitly designed for routine use by biomedical researchers in their own labs, the Accuri C6 Flow Cytometer(TM) is a full featured bench-top cell analysis system. For a limited time, Accuri is conducting beta tests of the Accuri C6 Flow Cytometer System with selected users. For more information about this program or about Accuri and the C6 Flow Cytometer series, visit www.accuricytometers.com
About Accuri Cytometers
Accuri Cytometers, Inc. is an Ann Arbor based life sciences company developing revolutionary high performance cell analysis systems designed to bring the power of flow cytometry into the labs of life sciences researchers everywhere. Reflecting the input of hundreds of researchers, the Accuri C6 Flow Cytometer(TM) is a full featured bench-top cell analysis system that provides all of the capabilities of industry-leading flow cytometers in an easy-to-use format and at a fraction of their cost. The Accuri system was engineered from the start to be compact, powerful and user-friendly, while also being affordable by most research laboratories. The Accuri C6 Flow Cytometer System is currently in beta testing. For more information, visit www.accuricytometers.com
Contacts: Accuri Cytometers: Media: Jennifer A. Baird Barbara Lindheim Chief Executive Officer GendeLLindheim BioCom Partners (734) 994-8000 (212) 918-4650
Accuri Cytometers, Inc.
CONTACT: Jennifer A. Baird, Chief Executive Officer of Accuri Cytometers,+1-734-994-8000; or media, Barbara Lindheim of GendeLLindheim BioComPartners for Accuri Cytometers, +1-212-918-4650
Web site: http://www.accuricytometers.com/
